<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077946</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-4161</org_study_id>
    <secondary_id>U1111-1151-9632</secondary_id>
    <nct_id>NCT02077946</nct_id>
  </id_info>
  <brief_title>A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden</brief_title>
  <official_title>A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this study is to investigate a retrospective
      database assessment of clinical effectiveness in type 2 diabetes patients treated with
      liraglutide from primary care centers in Sweden.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2014</start_date>
  <completion_date type="Actual">September 3, 2014</completion_date>
  <primary_completion_date type="Actual">September 3, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only)</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (NGSP standard, in %) change</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight (in kilograms)</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure (systolic, in mmHg)</measure>
    <time_frame>From baseline to 180 days of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids (HDL, LDL and triglycerides, in mmol/L)</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine</measure>
    <time_frame>Day 0, Day 180</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1059</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>No treatment given.</description>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>No treatment given.</description>
    <arm_group_label>Liraglutide / Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data will be analyzed for patients with type 2 diabetes treated with liraglutide or
        sitagliptin from January 2010 to December 2013, with a treatment length of 180 days.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from EMR (electronic medical record) system in the primary care in Sweden

          -  Patients equal to or more than 18 years of age

          -  Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013

          -  Minimum of 180 days of prior follow-up/history within the database before their index
             date

        Exclusion Criteria:

          -  Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes
             related)

          -  Female patients with gestational diabetes during pregnancy

          -  Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl
             peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>202 15</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <reference>
    <citation>Lind M, Matsson PO, Linder R, Svenningsson I, Jørgensen L, Ploug UJ, Gydesen H, Dorkhan M, Larsen S, Johansson G. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. Diabetes Ther. 2016 Jun;7(2):321-33. doi: 10.1007/s13300-016-0173-z. Epub 2016 May 23.</citation>
    <PMID>27216947</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

